Gideon M. Blumenthal, MD, Paul A. Bunn, MD, Jamie E

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed.

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging.

Mark F. Berry, MD, Thomas A. Sporn, MD, Joseph O. Moore, MD, Thomas A

Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation Andrea L.H. Arnett, MD, PhD, Kenneth.

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced.

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Victoria Wang, MD, PhD, Trever Bivona, MD, PhD

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung.

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma Taylor M.

An Unusual Metastatic Site for Primary Lung Cancer: The Spleen

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy Apar Pataer, MD, PhD, Neda Kalhor,

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis Whitney S. Brandt, MD, Wanpu.

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

Robert Pirker, MD, Felix J. F. Herth, MD, PhD, FCCP, Keith M

Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer Alberto Chiappori,

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

P2.03b-023 Circulating Tumor DNA (ctDNA)-Based Genomic Profiling of Known Cancer Genes in Lung Squamous Cell Carcinoma (LUSC) Vincent Lam, Hai Tran,

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer Walter Weder, MD, Stéphane Collaud, MD,

Stefano Occhipinti, PhD, Jeff Dunn, PhD, Dianne L

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis Sinéad A. Noonan,

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer Stephen A. Barnett, MBBS, Robert.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

A 10-Year Single-Center Experience on 708 Lung Metastasectomies: The Evidence of the “International Registry of Lung Metastases” Monica Casiraghi, MD,

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench Kenichi Suda, MD, PhD, Paul A. Bunn,

Feiran Lou, MD, MS, Camelia S. Sima, MD, MS, Prasad S

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Natural History and Factors Associated with Overall Survival in Stage IV ALK- Rearranged Non–Small Cell Lung Cancer Jose M. Pacheco, MD, Dexiang Gao,

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

S768I Mutation in EGFR in Patients with Lung Cancer

A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage Sara de Cabanyes Candela, MD, Frank.

Nabil P. Rizk, MD, Venkatraman E. Seshan, PhD, Manjit S

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience Lynette M. Sholl, MD, Dara.

Nicholas W. Choong, MD, Robert S. Hellman, MD

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed.

Saiama N. Waqar, M. B. B. S. , MSCI, Philip D

Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications.

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Follow-Up of Small (4 mm or Less) Incidentally Detected Nodules by Computed Tomography in Oncology Patients: A Retrospective Review Reginald F. Munden,

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and.

Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development.

KEYNOTE-024: Unlocking a pathway to lung cancer cure?

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Michelle S

Farhood Farjah, MD, MPH, David R. Flum, MD, MPH, Scott D

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

The IASLC Lung Cancer Staging Project

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer Gideon M. Blumenthal, MD, Paul A. Bunn, MD, Jamie E. Chaft, MD, Caroline E. McCoach, MD, PhD, Edith A. Perez, MD, Giorgio V. Scagliotti, MD, PhD, David P. Carbone, MD, PhD, Hugo J.W.L. Aerts, PhD, Dara L. Aisner, MD, PhD, Jonas Bergh, MD, PhD, Donald A. Berry, PhD, Anthony Jarkowski, PharmD, BCOP, Nicholas Botwood, MD, Darren A.E. Cross, PhD, Max Diehn, MD, PhD, Nicole L. Drezner, MD, Robert C. Doebele, MD, PhD, Collin M. Blakely, MD, PhD, Wilfried E.E. Eberhardt, MD, Enriqueta Felip, MD, PhD, Luca Gianni, MD, Steven P. Keller, MD, PhD, Patrick J. Leavey, MD, Shakun Malik, MD, Francesco Pignatti, MD, MSc, Tatiana M. Prowell, MD, Mary W. Redman, PhD, Naiyer A. Rizvi, MD, Rafael Rosell, MD, Valerie Rusch, MD, Dirk de Ruysscher, MD, PhD, Lawrence H. Schwartz, MD, Rajeshwari Sridhara, PhD, Rolf A. Stahel, MD, Stephen Swisher, MD, Janis M. Taube, MD, MSc, William D. Travis, MD, Patricia Keegan, MD, Jacinta R. Wiens, PhD, Ignacio I. Wistuba, MD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD, Mark G. Kris, MD Journal of Thoracic Oncology Volume 13, Issue 12, Pages 1818-1831 (December 2018) DOI: 10.1016/j.jtho.2018.09.017 Copyright © 2018 Terms and Conditions

Figure 1 LCMC4 PROMISE. Schema of the proposed trial of the Lung Cancer Mutation Consortium (LCMC) to identify oncogenic drivers at diagnosis and to match targeted neoadjuvant therapies to the drivers detected in patients with early stage lung cancer. CT, computed tomography; PET, positron-emission tomography; ctDNA, circulating tumor DNA. Journal of Thoracic Oncology 2018 13, 1818-1831DOI: (10.1016/j.jtho.2018.09.017) Copyright © 2018 Terms and Conditions

Figure 2 Method for assessment of percentage of viable residual tumor in resection specimens following neoadjuvant therapy.59,60 Journal of Thoracic Oncology 2018 13, 1818-1831DOI: (10.1016/j.jtho.2018.09.017) Copyright © 2018 Terms and Conditions